Aim To investigate the association of parameters of lipid profile and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 calculated by the Modification of Diet in Renal Disease (MDRD) in non-dialysis kidney patients. Methods The observational, case-control study enrolled patients (n=117) recruited from the Nephrological Counselling Centre of the University Clinical Centre Sarajevo and divided into two groups: group 1 eGFR (15-59 mL/min/1.73 m 2), and group 2 (control) eGFR ≥ 60 mL/min/1.73 m 2. Concentration of lipids, lipoproteins and apolipoproteins was measured, and atherogenic index of plasma (AIP; log(TG/HDLc)) was calculated. Results High density lipoprotein cholesterol (HDLc) and apolipoprotein E (APOE) concentrations in serum were reduced [(1.02 (0.94-1.29) vs 1.15 (1.1-1.4) mmol/L; p=0.009 and 0.035 (0.026-0.04) vs 0.041 (0.034-0.05) g/L; p=0.002, respectively)], while AIP was higher in group 1 than in group 2 (0.19±0.03 vs 0.09±0.04; p=0.013). Values less than 1.09 mmol/L and 0.038 g/L for HDLc and APOE, or higher than 0.165 for AIP (p<0.05) were associated with the eGFR below 60 ml/min/1.73 m 2. The age [OR = 1.1; 95% CI (1.05-1.17)] and AIP [OR = 8.7; 95% CI (1.18-65.0)] were independent positive predictors, while APOE was a negative predictor of eGFR reduction rate (OR=0.01; 95% CI (0.001-0.033; p<0.001). Conclusion Changes in parameters such as HDLc, APOE and AIP are associated with CKD. The study results imply the need of the AIP calculation as routine laboratory work due to its role along with the age and APOE in the prediction of renal function decline.
Parmar J, Joshi A, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014. p. 396–7.
2.
Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017. p. 35–45.
3.
Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004. p. 188–205.
4.
Chang J, Paulson C, Smith R. Apolipoproteins for cardiovascular risk assessment. Am Fam Physician. Online; 2014.
5.
Kaneva A, Potolitsyna N, Bojko E, Odland J. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers. 2015. p. 591454.
6.
Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo L, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009. p. 757–65.
7.
Dobiášová M, Frohlich J, Šedová M, Cheung M, Brown B. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011. p. 566–71.
8.
Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. The Open Cardiovasc Med J. 2011. p. 41–8.
9.
Miyatakea N, Shikatab K, Makinob H, Numata T. Relationship between estimated glomerular filtration rate (eGFR) and metabolic syndrome in japanese. Acta Med Okayama. 2010. p. 203–8.
10.
Xue L, Lou Y, Feng X, Wang C, Ran Z, Zhang X. Prevalence of chronic kidney disease and associated factors among the Chinese populations in Taian. BMC Nephrol. 2014. p. 205.
11.
Khatiwada S, Rajendra K, Gautam S, Lamsal M, Baral N. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. BMC Endocr Disord. 2015. p. 65.
12.
Lovre D, Shah S, Sihota A, Fonseca V. Managing diabetes and cardiovascular risk in chronic kidney disease patients. Endocrinol Metab Clin North Am. 2018. p. 237–57.
13.
Levey A, Inker L, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis. 2014. p. 820–34.
14.
Kidney Disease: Improving Global Outcomes (KDI-GO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013. p. 1–150.
15.
Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. p. 499–502.
16.
Dobiásová M. AIP-atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006. p. 64–71.
17.
Rahman M, Yang W, Akkina S, Alper A, Anderson A, Appel L, et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am SocNephrol. 2014. p. 1190–8.
18.
Corsetti J, Gansevoort R, Bakker S, Navis G, Sparks C, Dullaart R. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of highdensity lipoprotein cholesterol and C-reactive protein. Metabolism. 2012. p. 996–1002.
19.
Malarkodi V, Malathi M. Dyslipidemia correlating with reduced glomerular filtration rate in apparently healthy individuals. IJCBR. 2017. p. 198–200.
20.
Baragetti A, Norata G, Sarcina C, Rastelli F, Grigore L, Garlaschellik, et al. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med. 2013. p. 252–62.
21.
Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016. p. 886–96.
22.
Balode A, Khan Z. Serum lipid profile in chronic kidney disease patients on haemodialysis. IJAR. 2013. p. 20–2.
23.
Chen S, Hung C, Kuo M, Lee J, Chiu Y, Chang J, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoSOne. 2013. p. 55643.
24.
Lin J, Terembula K, K, Wilson R, F. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrology. 2015. p. 130.
25.
Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs and Ther. 2016. p. 87–100.
26.
Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012. p. 397–407.
27.
Hermans M, Ahn S, Rousseau M. log(TG)/ HDL-C is related to both residual cardiometabolic risk and beta-cell function loss in type 2 diabetes males. Cardiovasc Diabetol. 2010. p. 88.
28.
Hermans M, Ahn S, Rousseau M. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012. p. 132.
29.
Onat A, Can G, Kaya H, Hergenc G. Atherogenic index of plasma (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010. p. 89–98.
30.
Lee M, Park J, Han S, Kim Y, Kim Y, Yang C, et al. The atherogenic index of plasma andthe risk of mortality in incident dialysis patients: results from a nationwide prospective cohort in Korea. PLoS One. 2017. p. 177499.
31.
Adejumo O, Okaka E, Ojogwu L. Lipid profile in pre-dialysis chronic kidney disease patients in southern Nigeria. Ghana Med J. 2016. p. 44–9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
